JP2020500005A5 - - Google Patents

Download PDF

Info

Publication number
JP2020500005A5
JP2020500005A5 JP2019518550A JP2019518550A JP2020500005A5 JP 2020500005 A5 JP2020500005 A5 JP 2020500005A5 JP 2019518550 A JP2019518550 A JP 2019518550A JP 2019518550 A JP2019518550 A JP 2019518550A JP 2020500005 A5 JP2020500005 A5 JP 2020500005A5
Authority
JP
Japan
Prior art keywords
antigen
binding protein
seq
klebsiella
pneumoniae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019518550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500005A (ja
JP7160484B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/056725 external-priority patent/WO2018075375A1/en
Publication of JP2020500005A publication Critical patent/JP2020500005A/ja
Publication of JP2020500005A5 publication Critical patent/JP2020500005A5/ja
Application granted granted Critical
Publication of JP7160484B2 publication Critical patent/JP7160484B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019518550A 2016-10-19 2017-10-16 抗o1抗体およびその使用 Active JP7160484B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662410005P 2016-10-19 2016-10-19
US62/410,005 2016-10-19
PCT/US2017/056725 WO2018075375A1 (en) 2016-10-19 2017-10-16 Anti-o1 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2020500005A JP2020500005A (ja) 2020-01-09
JP2020500005A5 true JP2020500005A5 (https=) 2020-11-19
JP7160484B2 JP7160484B2 (ja) 2022-10-25

Family

ID=62019658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019518550A Active JP7160484B2 (ja) 2016-10-19 2017-10-16 抗o1抗体およびその使用

Country Status (12)

Country Link
US (3) US11117956B2 (https=)
EP (1) EP3529273A4 (https=)
JP (1) JP7160484B2 (https=)
KR (1) KR20190064636A (https=)
CN (1) CN109843917B (https=)
AU (1) AU2017346488A1 (https=)
BR (1) BR112019007147A2 (https=)
CA (1) CA3039686A1 (https=)
EA (1) EA201990895A1 (https=)
IL (1) IL266049A (https=)
SG (1) SG11201903063UA (https=)
WO (1) WO2018075375A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190077306A (ko) 2016-08-05 2019-07-03 메디뮨 엘엘씨 항-o2 항체 및 이의 용도
US11117956B2 (en) 2016-10-19 2021-09-14 Medimmune, Llc Anti-O1 antibodies and uses thereof
MX2021014984A (es) * 2019-06-06 2022-01-24 Nomad Bioscience Gmbh Klebicinas para el control de klebsiella.
WO2021186398A1 (en) 2020-03-19 2021-09-23 Medimmune Limited Anti-klebsiella pneumoniae antibodies and uses thereof
CN120775040A (zh) * 2021-08-25 2025-10-14 北京三诺佳邑生物技术有限责任公司 特异性识别肺炎克雷伯菌o1抗原的抗体及其应用
US20250066458A1 (en) * 2021-12-06 2025-02-27 Beijing Solobio Genetechnology Co., Ltd. Bispecific Antibodies Specifically Binding to Klebsiella Pneumoniae O2 Antigen and O1 Antigen and Compositions Thereof
IT202300000924U1 (it) * 2023-01-23 2024-12-22 Philomena Dove Cucitura all-up leggins seamless
CN118620072A (zh) * 2023-12-27 2024-09-10 上海博钒生物科技有限公司 一种肺炎克雷伯菌多糖单克隆抗体、其杂交瘤细胞株及其应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5179018A (en) 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
IE921342A1 (en) 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6360513B1 (en) 1999-05-11 2002-03-26 Sargento Foods Inc. Resealable bag for filling with food product(s) and method
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20030020733A1 (en) 2001-07-24 2003-01-30 Yin Memphis Zhihong Computer display having selective area magnification
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス,インコーポレーテッド 変異型Fc領域を含む抗体の同定および作製ならびにその利用法
CN102408483B (zh) 2003-07-15 2016-06-08 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
CA2621371C (en) 2005-09-07 2018-05-15 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
EP2489673A3 (en) 2007-05-02 2012-09-12 Intercell AG Klebsiella antigens
NZ587440A (en) * 2008-02-05 2013-01-25 Pfizer Antibodies specific for human integrin alpha 5 - beta 1 and their uses for treating tumours
US8271784B2 (en) 2009-10-15 2012-09-18 International Business Machines Corporation Communication between key manager and storage subsystem kernel via management console
PL3326643T3 (pl) 2009-12-06 2021-10-25 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania
SG10201505217WA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
AU2013229488B2 (en) 2012-03-08 2017-12-07 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
WO2014027697A1 (en) * 2012-08-13 2014-02-20 Kyowa Hakko Kirin Co., Ltd. Anti-pneumococcal surface protein (psp) monoclonal antibody
CN113620933A (zh) 2012-10-05 2021-11-09 卡德门企业有限公司 Rho激酶抑制剂
EP3142700B1 (en) 2014-05-16 2021-03-03 Medimmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
RU2021131224A (ru) * 2015-02-17 2021-11-03 Х4 Фармасьютикалз (Австрия) ГмбХ Антитела, нацеленные на о-антиген на основе галактана из k. pneumoniae
HK1252350A1 (zh) 2015-08-24 2019-05-24 Medimmune, Llc Mrka多肽、抗体及其用途
AU2016336901A1 (en) * 2015-10-16 2018-05-10 Arsanis Biosciences Gmbh Bactericidal monoclonal antibody targeting Klebsiella pneumoniae
KR20190077306A (ko) 2016-08-05 2019-07-03 메디뮨 엘엘씨 항-o2 항체 및 이의 용도
US11117956B2 (en) 2016-10-19 2021-09-14 Medimmune, Llc Anti-O1 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2020500005A5 (https=)
AU2018241107B2 (en) Antibodies to s. aureus surface determinants
US9803009B2 (en) Immunobinders directed against TNF
AU2017237543B2 (en) Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same
HRP20201975T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
HRP20201345T1 (hr) Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba
HRP20110599T1 (hr) Antitijela protiv toksina clostridium difficile i njihove primjene
JP7160484B2 (ja) 抗o1抗体およびその使用
JP2014519334A5 (https=)
CN106456767A (zh) 多细菌感染的治疗
CN109689090B (zh) 抗o2抗体及其用途
JP7830445B2 (ja) インターロイキン1アルファに特異的な真のヒト抗体
JP2018527924A5 (https=)
RU2018107056A (ru) Полипептиды mrka, антитела к ним и пути их применения
JP2016501877A5 (https=)
WO2022073102A1 (en) TRUE HUMAN ANTIBODY SPECIFIC FOR INTERLEUKIN 1 ALPHA (IL-1α)
JP2023545005A (ja) インターロイキン1アルファに特異的な真のヒト抗体
JP2023545007A (ja) インターロイキン1アルファに特異的な真のヒト抗体
KR20210126641A (ko) 보체 및 표적 항원에 결합하기 위해 이중 특이적 항체를 사용하는 조성물 및 방법
JP2018531625A5 (https=)
JP2021500865A (ja) スタフィロコッカス(Staphsylococcus)標的抗原および補体成分に結合する二重特異性抗原結合分子ならびにその使用
KR20230083288A (ko) 코로나바이러스 스파이크 단백질에 대한 단일클론 항체, 및 이의 용도
CN111356702A (zh) 抗pd-l1抗体及其抗原结合片段
US20220153818A1 (en) Antibody molecules and uses thereof
WO2022045173A1 (ja) 抗マラリア原虫抗体